The Company has three product candidates in clinical trials aimed at treating vascular disorders and improving cord blood transplantation.
ALDAGEN also has commercialized two products, ALDEFLUOR and ALDECOUNT, that incorporate ALDAGEN’s unique stem cell marker technology. ALDECOUNT is a FDA-approved in vitro diagnostic use (IVD) product for the identification and enumeration of low side scatter, ALDHbr cells by flow cytometry. ALDAGEN began laying the foundation for its technology and clinical approach by introducing ALDEFLUOR as a research use only (RUO) product. ALDEFLUOR has been quickly become a valued tool in the stem cell research community as it has been sold to over 100 labs worldwide.
